Co-administration of a CYP3A4 inhibitor (ketoconazole) increased the bioavailability of CS-7017 but did not affect tolerability: results from an open-label, phase I, two-way crossover study in healthy subjects

被引：0
|
作者：
Senaldi, G. [1 ]
Zahir, H. [1 ]
He, L. [1 ]
Rasmussen, J. C. [2 ]
Liu, K. [3 ]
Scheyer, R. [1 ]
机构：
[1] Daiichi Sankyo Pharma Dev, Translat Med, Edison, NJ USA
[2] MDS Pharma Serv, DMPK & Drug Safety Assessment, New York, NY USA
[3] Daiichi Sankyo Pharma Dev, Biostat, Edison, NJ USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72033-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：104 / 105
页数：2
相关论文
共 5 条
  • [1] The gastric modifier esomeprazole did not affect the bioavailability and tolerability of CS-7017 in an open-label, phase I, two-way crossover clinical study in healthy subjects
    Scheyer, R.
    Zahir, H.
    Luo, R.
    He, L.
    Noveck, R.
    Liu, K.
    EJC SUPPLEMENTS, 2010, 8 (07): : 101 - 101
  • [2] Food does not affect the pharmacokinetics of CS-7017 in healthy subjects: results from an open label, phase I, two-treatment, three-period, crossover study
    Scheyer, R.
    Zahir, H.
    Luo, R.
    He, L.
    Noveck, R.
    Liu, K.
    EJC SUPPLEMENTS, 2010, 8 (07): : 104 - 104
  • [3] Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study
    Moreno, Irene
    Hernandez, Tatiana
    Calvo, Emiliano
    Fudio, Salvador
    Kahatt, Carmen
    Fernandez, Cristian
    Iglesias, Jorge Luis
    Corral, Gema
    Perez-Ramos, Laura
    Montilla, Lola
    Zeaiter, Ali
    Lubomirov, Rubin
    PHARMACEUTICALS, 2024, 17 (02)
  • [4] Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects A single, randomized, two-way cross-over, open-label phase I study
    Izquierdo, Inaki
    Borja, Javier
    Rovira, Sandra
    Pelagio, Pilar
    Torres, Ferran
    Cebrecos, Jesus
    Garcia-Rafanell, Julian
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2010, 60 (01): : 36 - 41
  • [5] Effect of the CYP3A Inhibitor Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors: A Prospective, Multicenter, Open-Label, Randomized, Two-Way Crossover Drug-Drug Interaction Study
    Venkatakrishnan, Karthik
    Rader, Michael
    Ramanathan, Ramesh K.
    Ramalingam, Suresh
    Chen, Eric
    Riordan, William
    Trepicchio, William
    Cooper, Michael
    Karol, Michael
    von Moltke, Lisa
    Neuwirth, Rachel
    Egorin, Merrill
    Chatta, Gurkamal
    CLINICAL THERAPEUTICS, 2009, 31 : 2444 - 2458
1